Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
28 January, 2022 02:36 IST
Venus Remedies receives nod under PLI Scheme
Source: IRIS | 09 Dec, 2021, 01.45PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Venus Remedies, a research based pharmaceutical company, has received approval from the Government of India under PLI 2.0 of the Production Linked Incentive (PLI) Scheme for manufacturers of pharmaceutical goods registered in India.

Venus is one of the 10 non-MSME pharmaceutical companies under category-C which have been granted approval under the PLI Scheme.

As per the scheme, the Company will be eligible for incentive for the financial years 2022-23 to 2027-28, subject to fulfillment of minimum investment criteria and based on incremental sales of eligible products as per the scheme guidelines.

Shares of the company gained Rs 27.65, or 5.88%, to trade at Rs 497.70.  The total volume of shares traded was 31,750 at the BSE (12.18 p.m, Thursday).


 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Zensar Technologies Q3FY22 Review- Long term prospect looks attractive - 27-Jan-2022 15:00
Maruti Suzuki India Q3FY22 Review-Super bullish and expect 24% upside - 27-Jan-2022 14:33
Federal Bank Q3FY22 Review-Stressed assets stable at 2.6%; RoA at 1% - 27-Jan-2022 14:21
Welspun India joins global coalition to undertake climate action - 27-Jan-2022 13:03
Maruti Suzuki: Above estimate; strong recovery in market share and margin - 27-Jan-2022 12:49
APL Apollo Tubes Q3FY22 Review-Margin strong despite weak volumes - 27-Jan-2022 10:44
Cera Sanitaryware Q3FY22 Review-A positive surprise on margins front; Buy - 26-Jan-2022 11:01
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer